-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Fluvoxamine maleate is a selective serotonin reuptake inhibitor (SSRI) used to treat various psychiatric disorders such as obsessive-compulsive disorder, social anxiety disorder, and depression.
In the chemical industry, it is synthesized through a series of chemical reactions that involve the use of various reagents, solvents, and catalysts.
The synthesis of Fluvoxamine maleate can be divided into several steps, each of which requires careful attention to detail to ensure optimal yield and purity.
The first step in the synthesis of Fluvoxamine maleate involves the preparation of the starting material, which is a substituted phenethylamine.
This is achieved through reaction of 2-chlorphenethylamine with para-substituted anilines in the presence of a Base such as sodium hydroxide.
The resultant product is then treated with a Lewis acid catalyst, such as aluminum chloride, to introduce the desired substitution.
The next step involves the condensation of the substituted phenethylamine with a substituted phenylamine to form a biaryl compound.
This is achieved through a condensation reaction using a condensation agent such as dicyclohexylcarbodiimide (DCC) and hydroxybenzotriazole (HOBT) in the presence of a solvent such as dimethylformamide (DMF).
The resultant product is then treated with a strong base such as sodium hydroxide to quench the DCC.
The biaryl compound is then converted into a protected amino acid by reaction with a reactive amino acid derivative such as chloroacetic acid in the presence of a base such as triethylamine.
The resultant product is then treated with a p-toluenesulfonic acid, followed by a protecting group such as t-butyldimethylsilyl chloride (TBDMSCl) to form the desired protected amino acid derivative.
The final step in the synthesis of Fluvoxamine maleate involves the conversion of the protected amino acid derivative into the final product.
This is achieved through a series of chemical reactions that involve the use of reagents such as hydrogen chloride, methylene chloride, and sodium hydroxide, as well as a catalyst such as triethylamine.
The resultant product is then purified through chromatography to remove any unwanted impurities.
Overall, the synthesis of Fluvoxamine maleate involves a series of carefully planned chemical reactions that require precise control of reaction conditions, such as temperature, solvent, and catalyst, to ensure optimal yield and purity.
The purification step is also critical to remove any impurities that may affect the efficacy or safety of the final product.
It is important to note that the synthesis of Fluvoxamine maleate should only be carried out by trained professionals in a controlled laboratory setting, due to the potential hazards associated with the use of reagents and chemicals.